RIC ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 22 | もやもや病 | 1 |
22. もやもや病
臨床試験数 : 14 / 薬物数 : 21 - (DrugBank : 14) / 標的遺伝子数 : 28 - 標的パスウェイ数 : 44
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04012268 (ClinicalTrials.gov) | July 15, 2019 | 3/7/2019 | The Safety and Efficacy of RIC on Adult Moyamoya Disease | The Safety and Effect of Remote Ischemic Conditioning on Adult Moyamoya Disease | Moyamoya Disease | Device: RIC;Drug: Aspirin | Capital Medical University | NULL | Completed | 18 Years | 60 Years | All | 30 | N/A | China |